
Euphoria in Milan: Italian Nanophoria closes €83m financing round in heart failure
Italian biotech company NanoPhoria Bioscience has raised €83.5 million in a record-breaking Series A round to accelerate development of its lead therapy for heart failure with reduced ejection fraction (HFrEF) and expand its proprietary nano-in-micro drug …